ASPIRE Workshop 4: Study Procedures and Data Elements, Sources, Uses, and Issues Thomas Delate, PhD, MS.

Slides:



Advertisements
Similar presentations
Impact of an antidepressant adherence program in a managed care organization Kara Zivin Bambauer, PhD Stephen Soumerai, ScD Alyce Adams, PhD Fang Zhang,
Advertisements

1 TennCare Diabetes Program Evaluation Presentation to AcademyHealth Kenton Johnston, MPH, MS, MA June 4, 2007 An Individually-Matched Control Group Evaluation.
Population Trends in the Incidence and Outcomes of Acute Myocardial Infarction Robert W. Yeh, MD MSc Massachusetts General Hospital Alan S. Go, MD Kaiser.
Comparator Selection in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2009.
Health-related quality of life in diabetic patients and controls without diabetes in refugee camps in Gaza strip: a cross-sectional study By: Ashraf Eljedi:
Writing a Research Protocol Michael Aronica MD Program Director Internal Medicine-Pediatrics.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
RACIAL DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AN ANALYSIS OF BETA-BLOCKER AND STATIN USE FOLLOWING HOSPITALIZATION FOR ACUTE MYOCARDIAL INFARCTION.
Chengbin Hu Obese and overweight: problem and how to control? Problem: More than 2 in 3 adults are considered to be overweight or obese. More.
The Effect of Quality Improvement on Racial Disparities in Diabetes Care Thomas D. Sequist, MD MPH Alyce S. Adams, PhD Fang Zhang, MS Dennis Ross-Degnan,
1 Copyright © 2011 by Saunders, an imprint of Elsevier Inc. Chapter 9 Examining Populations and Samples in Research.
Slide 1 Long-Term Care (LTC) Collaborative PIP: Medication Review Tuesday, October 29, 2013 Presenter: Christi Melendez, RN, CPHQ Associate Director, PIP.
Experimental Design making causal inferences Richard Lambert, Ph.D.
Risk of colorectal cancer in patients taking statins and NSAIDS Dr Yana Vinogradova, Prof Julia Hippisley-Cox, Dr Carol Coupland and Prof Richard Logan.
* Indicates p < 0.05 indicates p < 0.05 Evaluating Clinical Pharmacist Impact on Diabetes Control* Mary Ella Hill, Pharm. D. Candidate; Orijane Dalton,
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December, 2015.
ASPIRE Workshop 4: Study Procedures and Data Elements, Sources, Uses, and Issues Kari L Olson, BSc(Pharm), Pharm D, FCCP, BCPS.
Copyright © 2011, 2005, 1998, 1993 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 13: Boundary Setting in Experimental-Type Designs A deductive.
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
Jennifer King with Vaishali Patel, Matthew Swain, Michael Furukawa Office of the National Coordinator for Health IT (ONC) Health Information Exchange Capability.
The Impact of Smoking Cessation Interventions by Multiple Health Professionals Lawrence An, MD 1 ; Steven Foldes, PhD 2 ; Nina Alesci, PhD 1 ; Patricia.
Epidemiological Study Designs And Measures Of Risks (1)
Journal Club Curriculum-Study designs. Objectives  Distinguish between the main types of research designs  Randomized control trials  Cohort studies.
Chapter 9: Case Control Studies Objectives: -List advantages and disadvantages of case-control studies -Identify how selection and information bias can.
Do Short-Term Medical Trips Make a Difference in Treating NCDs? Mark Ryan, MD Goldie Chang, P3; Camille Hochheimer, PhD student; Marwah Khalid, MD; Dien.
Understanding Populations & Samples
Stats Methods at IC Lecture 3: Regression.
- Higher SBP visit-to-visit variability (SBV) has been associated
Sofija Zagarins1, PhD, Garry Welch1, PhD, Jane Garb2, MS
ASPIRE Workshop 3: Choosing Your Study Design and Population
ASPIRE Session 3: Study Procedures and Data Elements, Sources, Uses, and Issues Thomas Delate, PhD, MS.
ASPIRE Class 4 Study Procedures and Data Elements, Sources, Uses, and Issues Thomas Delate, PhD, MS Clinical Pharmacy Research Scientist.
The Association of Exposure to Adverse
Presentation Developed for the Academy of Managed Care Pharmacy
How stages of change can predict screening and brief intervention outcome for alcohol problems in young adult emergency department patients.
Patient Registries and Health Outcomes in Diabetes: A Retrospective Study Nipa Shah, MD1; Fern Webb, PhD1; Liane Hannah, BSH1; Carmen Smotherman, MS2;
Exercise Adherence in Patients with Diabetes: Evaluating the role of psychosocial factors in managing diabetes Natalie N. Young,1, 2 Jennifer P. Friedberg,1,
Sampling Population: The overall group to which the research findings are intended to apply Sampling frame: A list that contains every “element” or.
Biostatistics Case Studies 2016
Impact of State Reporting Laws on Central Line– Associated Bloodstream Infection Rates in U.S. Adult Intensive Care Units Hangsheng Liu, Carolyn T. A.
ASPIRE Study Procedures and Data Elements, Sources, Uses, and Issues
Sleep Patterns and Risk of Injury among Rural Minnesota Adolescents
CASE-CONTROL STUDIES Ass.Prof. Dr Faris Al-Lami MB,ChB MSc PhD FFPH
Presenter: Christi Melendez, RN, CPHQ
Population, Samples, and Sampling Descriptions
ASPIRE Workshop 5: Application of Biostatistics
Critical Reading of Clinical Study Results
ASPIRE Workshop 5: Application of Biostatistics
San Francisco Department of Public Health
ASPIRE Workshop 1: Conceiving the Research Idea
S1316 analysis details Garnet Anderson Katie Arnold
Kandeke C, Chibuta C, Banda D
Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2
Accepted 2 June Ryan Chen
Annals of Internal Medicine • Vol. 167 No. 12 • 19 December 2017
Impact Evaluation Methods
Risk adjustment using administrative and clinical data: model comparison
ASPIRE Workshop 1: Conceiving the Research Idea
Rational Order of Laboratory Tests in Cardiovascular Diseases
Quasi-Experimental Designs
Candice Preslaski, PharmD, BCPS, BCCCP
Critical Appraisal วิจารณญาณ
Module 4 Part 3 Operationalizing the Measures
IMPACT OF PHARMACIST DELIVERED CARE IN THE COMMUNITY PHARMACY SETTING
The Research Question Does changing prescription medication labels to conform to the United States Pharmacopeia (USP) patient-centered, more understandable,
ASPIRE Workshop 2: Choosing Your Study Design and Population
ASPIRE Workshop 5: Application of Biostatistics
HEC508 Applied Epidemiology
Karen Wooten, MA Elizabeth Luman, MS Lawrence Barker, PhD
Presentation transcript:

ASPIRE Workshop 4: Study Procedures and Data Elements, Sources, Uses, and Issues Thomas Delate, PhD, MS

Outline Example study data needs Review source(s) for data elements Identify the elements needed to calculate the sample size/power for 1o outcome Sample size calculation example Review sources of and options for addressing bias

Example Study Review Study Question: Among patients with DM eligible for statin therapy, does an intervention involving a letter, a pre-ordered statin prescription, and pharmacist counseling increase statin initiation compared to no intervention? 1o Outcome: Compare statin-start rate (i.e., purchase of a statin RX within 3 months after mailing date) between groups 2o Outcomes: Compare statin persistence rate (i.e., statin purchase 1 year after mailing date +/- 45 days) between groups Compare abnormal CK (>600) or ALT (>200) rate (i.e., at least one abnormal lab result within 6 months after mailing date) between groups Study Design: Quasi-experimental

Example Study Review Inclusion Criteria: KPCO member Age 40-80 years Diabetes diagnosis Total Cholesterol > 135 mg/dL No statin purchase in past year Exclusion Criteria: ALT > 60 or SCr > 2.0 in past year CK > 2x ULN in past 2 years Fibrate or cyclosporine Rx purchase w/in past 90 days

Data Sources Report of patients from the electronic health record (EHR) who have diabetes Membership in EHR (date of birth, membership status) Laboratory results from EHR (TC, ALT, SCr, CK) Pharmacy dispensings from EHR (statins, fibrates, cyclosporine)

Study Sample Size How many letters need to be sent to assess whether the intervention works? Need to know: Estimated % of statin starts without intervention Estimated % of statin starts with intervention (difference or ratio = effect size) Desired power (1-β) Significance level (α)

Study Sample Size Estimated % of statin starts without intervention: 10% Estimated % of statin starts with intervention: 20% Desired power (1-β): 80% Significance level (α): 0.05

Study Sample Size Elements http://www.select-statistics.co.uk/sample-size-calculator-two-proportions

What happens to the required sample size as the group difference increases? The required sample size increases The required sample size decreases There is no association between the required sample size and the reference proportion It is data dependent on whether the sample size increases or decreases Answer: B

What happens to the required sample size as the group difference increases? The required sample size increases The required sample size decreases There is no association between the required sample size and the reference proportion It is data dependent on whether the sample size increases or decreases Answer: B

What is the relationship between effect size and required sample size, with power and alpha remaining constant? The larger the effect size, the larger the required sample size The larger the effect size, the smaller the required sample size There is no association between the effect size and sample size It is data dependent whether the sample size increases or decreases Answer: B August 26, 2018 | © 2011 Kaiser Foundation Health Plan, Inc. For internal use only.

What is the relationship between effect size and required sample size, with power and alpha remaining constant? The larger the effect size, the larger the required sample size The larger the effect size, the smaller the required sample size There is no association between the effect size and sample size It is data dependent whether the sample size increases or decreases Answer: B August 26, 2018 | © 2011 Kaiser Foundation Health Plan, Inc. For internal use only.

Addressing Potential Study Bias With a quasi-experimental (i.e., non-randomized) study design, groups may be non-equivalent Sicker/healthier -or- more motivated/less motivated patients are over represented in one group (selection bias) Factors affecting both the exposure and outcome are present (confounding) Exposures/outcomes are not measured accurately (misclassification) How can we tell if groups are non-equivalent and if so, how do we address non-equivalence?

Addressing Potential Selection Bias Determine if patients who received the intervention were the similar to those who did not Calculate comorbidity/disease burden scores from historical patients and compare these values between clinics Compare patient characteristics between days of the week If not similar 1) Use clinics where patients are similar 2) Match patients on characteristic(s) 3) Stratified analysis Example: Patients residing in lower down-town may be sicker than those in suburban Highlands Ranch

Addressing Potential Confounding Assess (based on literature, provider input, own knowledge) what factors could affect the 1o outcome and compare between groups during analysis phase For example Distance from pharmacy Age Insulin use Use these factors in multivariate regression(s)

Addressing Potential Misclassification Can outcomes, characteristics, potential confounders be measured and are they accurate? Medication purchase from a non-network pharmacy Lab result not present Lab measurement technique changed so values are reported differently over time Need valid and reliable data sources for both groups

http://www.ASPIREKPCO.WEEBLY.COM August 26, 2018 | © 2011 Kaiser Foundation Health Plan, Inc. For internal use only.